Finance

Lists
Outlook: 71.4% bullish·0.0% bearish
Go to analysis
DHR:NYSE
Danaher Corp
$219.23
+0.81%
(+1.77) 1D
Oct 9, 11:21:20 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DHR...
Open
$216.91
High
$220.61
Low
$216.51
Mkt. cap
154.12B
Avg. vol.
4.06M
Volume
624.80K
Dividend
0.73%
Quarterly dividend
$0.40
Ex-dividend date
Sep 30, 2026
P/E ratio
38.92
52-wk high
$242.80
52-wk low
$160.93
EPS
$5.63
Beta
0.77
Shares outstanding
702.99M
No. of employees
59K
Open
$216.91
High
$220.61
Low
$216.51
Mkt. cap
154.12B
Avg. vol.
4.06M
Volume
624.80K
Dividend
0.73%
Quarterly dividend
$0.40
Ex-dividend date
Sep 30, 2026
P/E ratio
38.92
52-wk high
$242.80
52-wk low
$160.93
EPS
$5.63
Beta
0.77
Shares outstanding
702.99M
No. of employees
59K
News stories
From web sources and news partners
Profile
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing. The company is ranked 180th on the Fortune 500 and 241st on the Forbes Global 2000. Wikipedia
About Danaher Corp
CEORainer M. Blair
Employees59K
Founded1969
Headquarters-
SectorHealth care
Websitedanaher.com
Analyst ratings
Based on 17 analysts giving stock ratings to DHR in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for DHR in the last 3 months.
Highest
Current $219.23
$255.00 (+16.32%)
Average
$232.88 (+6.23%)
Lowest
$200.00 (-8.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ryskin
Bank of America Securities
Buy
Maintained
$255.00
+16.3%
10/09/2026
Luke Sergott
Barclays
Buy
Maintained
$255.00
+16.3%
10/07/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
$250.00
+14%
10/05/2026
Dan Leonard
RBC Capital
Buy
Maintained
$250.00
+14%
10/04/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$250.00
+14%
10/01/2026
Joanne Wuensch
Citi
Buy
Maintained
$230.00
+4.9%
09/21/2026
Tycho Peterson
Jefferies
Buy
Maintained
$210.00
-4.2%
09/18/2026
Doug Schenkel
UBS
Buy
Initiated
$250.00
+14%
09/13/2026
Lu Li
UBS
Buy
Initiated
$250.00
+14%
09/09/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$220.00
+0.4%
08/03/2026
David Westenberg
Piper Sandler
Hold
Maintained
$200.00
-8.8%
07/27/2026
David Toung
Argus Research
Buy
Reiterated
$230.00
+4.9%
07/23/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$220.00
+0.4%
07/23/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
$240.00
+9.5%
07/22/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/22/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$220.00
+0.4%
07/22/2026
Patrick B Donnelly
Citi
Buy
Maintained
$230.00
+4.9%
07/22/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
$195.00
-11.1%
07/22/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$236.00
+7.6%
07/22/2026
Aristotelis Moutopoulos
DZ BANK AG
Buy
Maintained
$210.00
-4.2%
07/22/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$230.00
+4.9%
07/06/2026
Unknown Analyst
DZ BANK AG
Buy
Initiated
$210.00
-4.2%
06/03/2026
Sidharth Sahoo
HSBC
Buy
Maintained
$230.00
+4.9%
06/03/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
06/01/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$200.00
-8.8%
05/14/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$245.00
+11.8%
04/22/2026
Ed Ridley-Day
Rothschild & Co Redburn
Hold
Maintained
$205.00
-6.5%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$230.00
+4.9%
04/14/2026
Next call in 12 days
Wed, Oct 21, 8:00 AM
Fiscal period
Q3 2026
- / $1.92
Revenue / Est. (USD)
- / 6.56B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
6.05B
6.84B
5.95B
6.26B
Cost of goods sold
2.53B
2.86B
2.36B
2.61B
Cost of revenue
2.53B
2.86B
2.36B
2.61B
Research and development expenses
378.00M
438.00M
387.00M
412.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.89B
2.03B
1.84B
2.01B
Operating expense
2.27B
2.46B
2.23B
2.42B
Total operating expenses
4.80B
5.32B
4.59B
5.03B
Operating income
1.26B
1.52B
1.36B
1.24B
Other non operating income
-
-87.00M
-
-
EBT including unusual items
1.08B
1.37B
1.24B
1.08B
EBT excluding unusual items
1.19B
1.39B
1.33B
1.19B
Income tax expense
168.00M
190.00M
206.00M
208.00M
Effective tax rate
15.61%
13.84%
16.68%
19.29%
Other operating expenses
-
-
-
-
Net income
908.00M
1.20B
1.03B
870.00M
Net profit margin
15.00%
17.51%
17.29%
13.89%
Earnings per share
1.89
2.23
2.06
1.94
Interest and investment income
3.00M
13.00M
27.00M
61.00M
Interest expense
-67.00M
-55.00M
-63.00M
-107.00M
Net interest expenses
-64.00M
-42.00M
-36.00M
-46.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.88B
2.14B
1.99B
1.90B
Gain or loss from assets sale
-9.00M
9.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps